YTYijun Tang

Yijun Tang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yijun Tang has a total of 14 co-authors. Here are the top co-authors by number of shared publications:

  • Xiumin Wang

    Department of Endocrinology and Metabolism, Shanghai Children’s Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China

    2 shared publications
  • Jian Wang

    International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China

    1 shared publication
  • Jiayi Wang

    Department of Urology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China

    1 shared publication
  • Jie Tang

    Department of Medical Genetics and Molecular Diagnostic Laboratory, Shanghai Children’s Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China

    1 shared publication
  • Juan Li

    Department of Endocrinology and Metabolism, Shanghai Children’s Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China

    1 shared publication
  • Qianwen Zhang

    Department of Endocrinology and Metabolism, Shanghai Children’s Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, China

    1 shared publication

Latest Publications

  • Open Access

    Uncovering Hidden Genetic Contributors to 46,XY Disorders of Sex Development Through Phenotype-Driven Rare Variant Assessment: A Pilot Study

    by Yijun Tang, Yao Chen, Qianwen Zhang, Jie Tang, Yu Ding, Juan Li, Tingting Yu, Xiumin Wang

    Background: Despite advances in genetic testing, many 46,XY Disorders of sex development (DSD) cases remain unsolved after whole-exome sequencing (WES). This study intended to explore rare variants in patients with micropenis, cryptorchidism, or hypospadias using bioinformatics analysis to identify potential pathogenic contributors and pathways underlying 46,XY DSD. Methods: A total of 35 patients with specific phenotypes (micropenis/cryptorchidism/hypospadias) and negative whole-exome sequencing results were enrolled. Bioinformatics analysis methods (SKAT-O test and GO enrichment) were applied to identify the putative loss-of-function (pLoF) variation, including nonsense, frameshift, and canonical splice-site variants, and predicted deleterious missense variants (CADD Phred > 20). Literature was reviewed to explore the correlation of detected candidate genes/pathways and 46,XY disorder of sex development. Results: After variant quality filtering, we identified 307,638 pLoF variants and 127,857 predicted deleterious missense variants across all samples. In subgroup A (micropenis, n = 21), we identified 146,268 pLoF variants and 104,746 predicted deleterious missense variants. In subgroup B (cryptorchidism, n = 10), we identified 111,172 pLoF variants and 77,244 predicted deleterious missense variants. In subgroup C (hypospadias, n = 4), we identified 50,198 pLoF variants and 23,111 predicted deleterious missense variants. Using SKAT-O with an initial screening threshold of p < 0.005 (FDR q < 0.05), we obtained 67 candidate genes from the pLoF variant set and 59 candidate genes from the predicted deleterious missense variant set in subgroup A; 81 and 11 candidate genes, respectively, in subgroup B; and 17 and 0 candidate genes, respectively, in subgroup C. Conclusions: Assessment of rare variants helps further explore the genetic contributors to 46,XY disorder of sex development and provide potential candidate genes and associated pathways.

  • Open Access

    Clinical characteristics and genetic expansion of 46,XY disorders of sex development children in a Chinese prospective study

    by Yijun Tang, Yao Chen, Jiayi Wang, Qianwen Zhang, Yirou Wang, Yufei Xu, Xin Li, Jian Wang, Xiumin Wang

    Diagnosis and management strategy of Disorders of sex development (DSD) is difficult and various due to heterogeneous phenotype and genotype. Under widespread use of genomic sequencing technologies, multiple genes and mechanism has been identified and proposed as genetic causes of 46, XY DSD. In this study, 178 46, XY DSD pa-tients were enrolled and underwent gene sequencing (either whole-exome sequencing or targeted panel gene sequencing). Detailed clinical phenotype and genotype information were summarized which showed that the most common clinical manifestations were micropenis (56.74%, 101/178), cryptorchidism (34.27%, 61/178), and hypospadias (17.42%, 31/178). Androgen synthesis/action disorders and idiopathic hypogonado-tropic hypogonadism were the most frequent clinical diagnoses, accounting respectively for 40.9% and 21.59%. From all next-generation sequencing results, 103 candidate var-iants distributed across 32 genes were identified in 88 patients. The overall molecular detection rate was 49.44% (88/178), including 35.96% (64/178) pathogenic/likely pathogenic (P/LP) variants and 13.48% (24/178) VUS (variants of uncertain significance). Of all, 19.42% (20/103) variants were first reported in 46, XY DSD patients. Mutation c.680G>A (p.R227Q) on SRD5A2 (Steroid 5 Alpha-reductase 2) (36.67%, 11/30) was a hotspot mutation in Chinese population. Novel candidate genes related to DSD [GHR (Growth Hormone Receptor), PHIP (Pleckstrin Homology domain Interacting Protein)] were identified. Overall, this was a large cohort of 46, XY DSD patients with a com-mon clinical classification and phenotype spectrum of Chinese patients. Targeted gene panel sequencing (TPS) covered most of the genes contributing to DSD, whereas whole exome sequencing (WES) detected more candidate genes.